Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanobiotix - Revenue for the second quarter of 2013

Abstract:
NANOBIOTIX (Euronext : NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the second quarter of 2013.

Nanobiotix - Revenue for the second quarter of 2013

Paris, France | Posted on July 13th, 2013

Income statement



in €


Q2 2013*


H1 2013

Revenue

of which :

License

Services

48,569

45,847

2,722

95,050

93,328

2,722

*over the second quarter of 2012, the company recorded no revenue

Activity

As in previous quarters, revenue recorded during the second quarter of 2013 corresponds to the pro rata share of the first payment received by the company within the framework of the licensing contract signed with PharmaEngine, the Taiwan-based biopharmaceutical company, in August 2012, which covers the development and commercialization of NBTXR3 in the Asia-Pacific region. This upfront payment amounts to €810,640, generating a product of €45,847 for the period and totalling €92,328 for the first semester in 2013. The invoicing of services totalled €2,722 for the period. In total, revenue for the second quarter amounts €48,569. Revenue for the first half of 2013 is €95,050 which is fully in line with Company expectations.

Nanobiotix remains focused on the clinical development of its lead products where commercialization is planned for 2017. Recent positive news flow, especially in June, indicates the successful implementation of Nanobiotix's strategy in line with the Company's development plan. In June, Nanobiotix published encouraging preliminary results for lead product NBTXR3 with clinical proof of concept, safety and security of the intratumoral injection in patients with soft tissue sarcoma. In parallel, Nanobiotix has received approval from ANSM to start a new clinical trial for NBTXR3 in head and neck cancer patients, a major concern in terms of public health in European countries and across Asia. Nanobiotix has also initiated the preclinical development of NBTX-IV, the second product from the NanoXray pipeline, through collaboration with the US National Cancer Institute (NCI).

Financial calendar

Results for the first half of 2013, on August 30, 2013

####

About Nanobiotix
Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product, NBTXR3 based on NanoXray, is currently under clinical development for soft tissue sarcoma. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. The Company is based in Paris, France.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

For more information, please click here

Contacts:
Nanobiotix

Laurent Levy
CEO
+33 (0)1 40 26 07 55


NewCap.
Financial communication
and investors relations
Louis-Victor Delouvrier
Emmanuel Huynh
+33 (0)1 44 71 98 53


Yucatan
Media relations (France)
Annie-Florence Loyer
Nadège Le Lezec
+33 (0)1 53 63 27 27
+33 (0)6 88 20 35 59


College Hill
Media relations (Outside France)
Melanie Toyne Sewell
Claire Dickinson
Donia Al Saffar
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment: Targeted therapy for hepatocellular carcinoma using nanotechnology August 27th, 2014

Scientists craft atomically seamless, thinnest-possible semiconductor junctions August 26th, 2014

RMIT delivers $30m boost to micro and nano-tech August 26th, 2014

Creation of a Highly Efficient Technique to Develop Low-Friction Materials Which Are Drawing Attention in Association with Energy Issues August 26th, 2014

Govt.-Legislation/Regulation/Funding/Policy

Introducing the multi-tasking nanoparticle: Versatile particles offer a wide variety of diagnostic and therapeutic applications August 26th, 2014

Scientists craft atomically seamless, thinnest-possible semiconductor junctions August 26th, 2014

Competition for Graphene: Berkeley Lab Researchers Demonstrate Ultrafast Charge Transfer in New Family of 2D Semiconductors August 26th, 2014

X-ray Laser Probes Tiny Quantum Tornadoes in Superfluid Droplets: SLAC Experiment Reveals Mysterious Order in Liquid Helium August 25th, 2014

Nanomedicine

The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment: Targeted therapy for hepatocellular carcinoma using nanotechnology August 27th, 2014

Introducing the multi-tasking nanoparticle: Versatile particles offer a wide variety of diagnostic and therapeutic applications August 26th, 2014

Symphony of nanoplasmonic and optical resonators leads to magnificent laser-like light emission August 26th, 2014

Silver Replaced with Copper Nanoparticles to Produce Antibacterial Fabrics August 25th, 2014

Announcements

The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment: Targeted therapy for hepatocellular carcinoma using nanotechnology August 27th, 2014

Creation of a Highly Efficient Technique to Develop Low-Friction Materials Which Are Drawing Attention in Association with Energy Issues August 26th, 2014

Competition for Graphene: Berkeley Lab Researchers Demonstrate Ultrafast Charge Transfer in New Family of 2D Semiconductors August 26th, 2014

Symphony of nanoplasmonic and optical resonators leads to magnificent laser-like light emission August 26th, 2014

Financial Reports

Harris & Harris Group Letter to Shareholders on Website August 19th, 2014

Arrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520 August 12th, 2014

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 August 12th, 2014

Harris & Harris Group Reports Financial Statements as of June 30, 2014 August 10th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE